Rhythm - where not all obesity is the same!
Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, a distinct subset of obesity resulting from genetic variants within the melanocortin-4 receptor (MC4R) pathway. These disorders result in the disruption of satiety signals and energy homeostasis in the body, which leads to excess or insatiable hunger, known as hyperphagia, and to severe, early-onset obesity. By leveraging cutting-edge insights and expertise in precision medicine, Rhythm is dedicated to pioneering groundbreaking therapies for these rare disorders. Learn more about the Rhythm pipeline and commitment to rare genetic disorders of obesity at www.rhythmtx.com.